Watch leading breast cancer clinicians from Europe and Japan discuss the latest data from the European Society for Medical Oncology (ESMO) 2018 Congress, Munich, Germany, and what they may mean for global and regional clinical practice.
THIS CONTENT IS AVAILABLE FOR FREE TO REGISTERED USERS You are not currently logged in. LOGIN or REGISTER to access this content
LOGIN or REGISTER to access this content
Immediate, and unrestricted free access to all resources
Bi-weekly scientific newsletters highlighting the latest emerging data and industry news
Access to your personalised learning profile and CME record.
Watch a series of internationally renowned clinical specialists from Europe and Japan discuss key clinical data of interest from the European Society for Medical Oncology (ESMO) 2018 Congress in Munich, Germany, 19-23 October 2018.
The potential implications of these data for optimizing clinical outcomes for patients with advanced breast cancer are explored from both global and regional perspectives.
The information in this activity is intended for oncologists, nurses, and other healthcare professionals involved in the treatment of patients with breast cancer.
After watching these touchCONGRESS Expert Opinions from ESMO 2018, you should:
Be familiar with key clinical data of interest for advanced breast cancer that were presented at the Congress and what they may mean for both global and regional clinical practice.
Understand whether these new data can help inform sequencing of therapies in patients with advanced breast cancer.
Be aware of whether prognostic and differentiation factors may drive the optimal use of chemotherapy, endocrine therapy and combination therapy with targeted agents such as CDK4/6 inhibitors.
Please feedback on this touchCONGRESS Expert Opinions on the following: (scale 1-5, 1 strongly disagree; 5 strongly agree).